Securities Claims Investigated Against Altimmune, Inc. Amid Financial Turmoil

Investigating Securities Fraud Claims Against Altimmune, Inc.

Background
Berger Montague, a well-respected law firm known for its expertise in securities class action litigation, is currently looking into potential securities fraud claims involving Altimmune, Inc. This clinical-stage biopharmaceutical company, listed under NASDAQ with the ticker symbol ALT, has come under scrutiny following a significant class action lawsuit filed on behalf of investors who acquired its securities between August 10, 2023, and June 25, 2025. The deadline for those impacted to seek lead plaintiff status is October 6, 2025.

What Happened?
Altimmune, headquartered in Gaithersburg, Maryland, faced severe financial backlash when, on June 26, 2025, it declared that its IMPACT study had failed to meet its primary endpoint: statistical significance in fibrosis reduction. The announcement cited a higher-than-anticipated placebo response as the reason for the dismal results. While company management had previously shared optimistic forecasts, they reacted to the announcement by downplaying the results, suggesting that the issues could be addressed in a later Phase 3 study.

Investor Reactions
The aftermath of this announcement was catastrophic for Altimmune's stock, which plunged by 53%. Prior to this disclosure, shares were valued at $7.71 each, but they plummeted to $3.61 in a single day, resulting in substantial losses for shareholders. Such dramatic stock movements raise serious concerns about the information that was previously available to investors, as well as whether management misled shareholders with unfounded optimism leading up to the disclosure.

The Role of Berger Montague PC
As a leading law firm specializing in securities litigation since 1970, Berger Montague has a robust track record of representing both individual and institutional investors. The firm is committed to holding corporations accountable for any misrepresentation that may affect shareholder rights and has vowed to ensure that those investors who suffered losses have the opportunity to express their grievances and seek compensation.

Next Steps for Investors
Anyone who purchased Altimmune securities during the specified class period should be aware of their rights and the potential to have their claims heard. Interested parties can click on the links provided to learn more about their options or directly contact the firm to discuss their cases further:

- Andrew Abramowitz, Senior Counsel, (215) 875-3015, [email protected]
- Caitlin Adorni, (267) 764-4865, [email protected]

Conclusion
The ongoing investigation by Berger Montague serves as a critical reminder of the importance of transparency within the biopharmaceutical sector. Investors of Altimmune, Inc. should remain vigilant and proactive in understanding their rights and options as developments in this case unfold. With the looming timeline for filing claims approaching, prompt action can make a significant difference in the potential outcome of this situation. As the investment landscape continues to evolve, it remains crucial that companies stay steadfast in their accountability to their shareholders.